Skip to search
Skip to main content
Back to Search
Start Over
Switching from natalizumab to fingolimod: risk of disease reactivation during the washout period is due to the previous activity of the disease. Follow-up of the ENIGM survey
Authors :
Cohen, M. Maillart, E. Papeix, C. Vukusic, S. Brassat, D. Seze, J. Tourbah, A. Wiertlewski, S. Laplaud, D. Camu, W. Courtois, S. Derouiche, F. Chambaud, L. Boulay, C. Brochet, B. Debouverie, M. Casez, O. Heinzlef, O. Ouallet, J. Stankoff, B. Castelnovo, G. Le Page, E. Defer, G. Derache, N. Anne, O. Berger, E. Camdessanche, J. Kopf, A. Fleury, M. Malikova, I. Pelletier, J. Al Khedr, A. Zaenker, C. Edan, G. Moreau, T. Fromont, A. Rico, A. Blanc, F. nicolas collongues Barth, P. Louiset, P. Pittion, S. Clavelou, P. Thaite, F. Vermersch, P. Sephir, H. Creange, A. Gout, O. Guennoc, A. Coustans, M. Thaurin, G. Lallement, F. Rouhart, F. Thouvenot, E. Labauge, P. Seeldrayers, P. Lebrun, C. Club Francophone Sclerose Plaques
Source :
ResearcherID
Details
Database :
OpenAIRE
Journal :
ResearcherID
Accession number :
edsair.dedup.wf.001..163ff3a7132d08c6cff6c20d74c9764b